Neuprozyme Therapeutics ApS: Financial statements 2020
CVR: 40010106
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -38,600 and a net result of DKK -35,542 compared with DKK -7,500 the year before. Equity in the 2020 report amounted to DKK 6,958. The solvency ratio was 11.1%.
- Gross Profit
- DKK -38,600
- Profit/Loss
- DKK -35,542
- Equity
- DKK 6,958
- Total Assets
- DKK 62,710
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -39K | -36K | 7K | 0 |
| 2019 | - | -8K | -8K | 43K | - |
| 2018 | - | - | 0 | 50K | - |
Official annual report
How creditworthy is Neuprozyme Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of October 28, 2020, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of Neuprozyme Therapeutics ApS.
As of October 28, 2020, ALBJERG STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of Neuprozyme Therapeutics ApS.
About Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.